Laura Francis Sells 757 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN - Get Free Report) CEO Laura Francis sold 757 shares of the business's stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $18.26, for a total value of $13,822.82. Following the transaction, the chief executive officer directly owned 362,141 shares of the company's stock, valued at approximately $6,612,694.66. The trade was a 0.21% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Laura Francis also recently made the following trade(s):

• On Monday, May 19th, Laura Francis sold 5,412 shares of SiBone stock. The stock was sold at an average price of $19.49, for a total value of $105,479.88.
• On Friday, May 16th, Laura Francis sold 12,385 shares of SiBone stock. The stock was sold at an average price of $19.67, for a total value of $243,612.95.
• On Wednesday, May 7th, Laura Francis sold 38,504 shares of SiBone stock. The stock was sold at an average price of $17.18, for a total value of $661,498.72.

SiBone Trading Down 2.5%

NASDAQ:SIBN traded down $0.46 on Monday, reaching $18.01. 344,646 shares of the stock traded hands, compared to its average volume of 395,174. The firm has a market capitalization of $767.59 million, a price-to-earnings ratio of -28.14 and a beta of 0.93. The company's 50 day moving average is $17.89 and its 200-day moving average is $16.23. The company has a current ratio of 8.53, a quick ratio of 7.26 and a debt-to-equity ratio of 0.21. SiBone has a 1-year low of $11.70 and a 1-year high of $20.05.

SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. The firm had revenue of $47.29 million for the quarter, compared to analysts' expectations of $45.13 million. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. Equities research analysts anticipate that SiBone will post -0.78 EPS for the current fiscal year.

Hedge Funds Weigh In On SiBone

A number of institutional investors and hedge funds have recently modified their holdings of SIBN. Nuveen LLC bought a new position in shares of SiBone in the 1st quarter worth $18,605,000. First Light Asset Management LLC lifted its holdings in shares of SiBone by 41.8% in the 1st quarter. First Light Asset Management LLC now owns 1,612,408 shares of the company's stock worth $22,622,000 after purchasing an additional 475,426 shares in the last quarter. Silvercrest Asset Management Group LLC lifted its holdings in shares of SiBone by 21.9% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company's stock worth $27,392,000 after purchasing an additional 350,970 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of SiBone by 11.1% in the 1st quarter. American Century Companies Inc. now owns 2,642,322 shares of the company's stock worth $37,072,000 after purchasing an additional 264,254 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in shares of SiBone by 55.0% in the 1st quarter. Victory Capital Management Inc. now owns 631,568 shares of the company's stock worth $8,861,000 after purchasing an additional 224,190 shares in the last quarter. 98.11% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

SIBN has been the subject of several research analyst reports. Needham & Company LLC reissued a "buy" rating and set a $24.00 target price on shares of SiBone in a research note on Tuesday, May 6th. Truist Financial boosted their target price on SiBone from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price objective on shares of SiBone in a research note on Tuesday, May 6th.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.